Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 32Ovarian Neoplasms 21Neoplasms 14Carcinoma, Hepatocellular 13Fallopian Tube Neoplasms 12Carcinoma, Non-Small-Cell Lung 9Endometrial Neoplasms 7Colonic Neoplasms 7Neoplasm Metastasis 6Squamous Cell Carcinoma of Head and Neck 4Glioblastoma 4Breast Neoplasms 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Rectal Neoplasms 3Lung Neoplasms 3Liver Neoplasms 3Biliary Tract Neoplasms 3Sarcoma 2Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Pancreatic Neoplasms 2Neuroma, Acoustic 2Neurofibromatosis 2 2Mouth Neoplasms 2Meningioma 2Lymphoid Interstitial Pneumonia 2Gastrointestinal Neoplasms 2Digestive System Neoplasms 2

Interventions

pembrolizumab 1fludarabine phosphate 1fludarabine 1Cyclophosphamide 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Microsatellite Instability × Bevacizumab × 30 days × Clear all
NCT06004245 2026-05-08

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

Vividion Therapeutics, Inc.

Phase 1 Recruiting
280 enrolled
Gastrointestinal

Colorectal Neoplasms, Microsatellite Instability

Data powered by HemOnc (CC BY 4.0) Colophon âš¡